By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Intellia Therapeutics 

130 Brookline Street, Suite 201

Cambridge  Massachusetts  02139  U.S.A.
Phone: 857-285-6200 Fax: n/a



Company News
Intellia And CRISPR (CRSP) Announce U.S. Patent Covering CRISPR/Cas9 Ribonucleoprotein Complexes 4/26/2017 10:32:20 AM
Patent Fight Continues as CRISPR (CRSP), Intellia, Caribou Biosciences and ERS Genomics Appeal CRISPR Decision 4/13/2017 8:19:07 AM
Intellia Announces European Patent Office’s Decision to Grant CRISPR/Cas9 Genome Editing Technology Patent 4/11/2017 9:29:40 AM
Intellia’s CEO Has Cambridge-Based Company Moving Forward on Positive in vivo Data 3/20/2017 6:38:02 AM
CRISPR (CRSP), Intellia, Caribou Biosciences And ERS Genomics Provide Update On CRISPR/Cas9 U.S. Patent Interference Proceedings And Grants Of Corresponding Patents In The U.K. 2/16/2017 7:06:22 AM
Roaring Intellia Moves Into New HQ, Allowing Company to Double Staff and Advance CRISPR/Cas9 Pipeline 12/2/2016 5:49:08 AM
Intellia Appoints Perry Karsen As Chairman Of Its Board Of Directors 4/25/2016 10:10:33 AM
Bay States's Intellia Discloses a $125 Million CRISPR/Cas Deal with Regeneron (REGN) and Files for $120 Million IPO 4/12/2016 6:10:07 AM
Booming Intellia Snaps Up Vertex (VRTX)'s Former Space Near Kendall Square, Hopes to Hire for Newly Created Division 1/22/2016 6:47:28 AM
Intellia Launches New Division To Accelerate Ex Vivo Programs With CRISPR/Cas9 1/12/2016 12:00:09 PM